Bucking the Big Pharma trend
Lead asset XF-73 has potential to be first to a $1.2bn core market. We think that its low...
Read moreDouble thumbs up for new bank facility
Refinancing loans can be a tricky exercise at the best of times, especially given today’s the...
Read moreStrong Q2 AUM update underpins FY19e
Excellent AUM growth for the three months to end March 2019 comprised net inflows of £0.5bn into...
Read moreTop of the Props
Looking at expected ungeared ROIs, Watkin Jones, a UK developer / manager of large scale, multi...
Read moreStrong FY18, growing operational resilience
Raven Property Group is a Guernsey registered property company specialising in investment and...
Read more£21m to fund unprecedented demand
There are a multitude of reasons why companies tap investors for money. However, to us the most...
Read moreForecasts trimmed, attractions intact
Impax is a market-leading manager of both listed and private equity funds, which invest in ways...
Read moreMomentum continues to build
The pressures associated with managing its uber-complex supply chain are immense. Having to not...
Read moreBulgin approach infers 'substantial' upside
Elektron (EKT) is a specialist niche product OEM and B2B operational service provider, enjoying a...
Read moreBig Data expert primed for major break-out
Forget the $, £‚ or €. Today, data is the world's #1 currency and the lifeblood of any ambitious...
Read moreBig game hunting
Kromek is pioneering digital colour imaging for x- and gamma rays, using cadmium zinc telluride...
Read more